Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is an Interleukin‑12/23 inhibitor presented as a biologic for intravenous use. It treats plaque psoriasis, psoriatic arthritis and Crohn's disease in adult patients. It is indicated for moderate to severe disease and is administered under specialist supervision.

GNH USA supplies Imuldosa as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and provides cold‑chain logistics to ensure product integrity. Clients receive regulatory documentation and support for import clearance.

Ustekinumab targets the interleukin‑12/23 pathway and is used in several immune‑mediated conditions.

Plaque psoriasis: significantly reduces the extent and severity of skin plaques, improving quality of life. Psoriatic arthritis: alleviates joint pain, swelling and stiffness, and can halt structural damage progression. Crohn's disease: helps achieve clinical remission and maintain disease control in moderate to severe cases.

Ustekinumab may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Upper respiratory tract infection - Headache - Fatigue - Infusion‑related reactions such as redness or mild pain at the site

Serious or Rare Side Effects: - Serious infections including tuberculosis and opportunistic pathogens - Malignancies such as lymphoma or skin cancer - Severe hypersensitivity reactions, including anaphylaxis - Cardiovascular events like myocardial infarction

Before initiating therapy, several safety considerations should be reviewed.

Screen for latent tuberculosis: perform testing and treat if positive before starting. Monitor for signs of infection: advise patients to report fever, cough, or unusual symptoms promptly. Assess malignancy history: evaluate risk factors and conduct appropriate cancer screenings. Avoid use in active serious infections: defer treatment until infection is resolved. Pregnancy and lactation: safety is unknown; discuss potential risks with a healthcare professional. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab can interact with other agents that affect immune function or vaccine efficacy.

Major Interactions (Avoid): - Live vaccines: contraindicated during treatment due to risk of infection. - Concurrent use of other potent immunosuppressants (e.g., azathioprine, cyclophosphamide) may markedly increase infection risk.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: may have reduced effectiveness; timing should be coordinated. - Systemic corticosteroids: may augment overall immunosuppression. - Antifungal agents that modulate immune response: monitor for additive effects. - Antiviral therapies for chronic infections: assess for potential overlapping immunosuppressive impact.